

Activities	Screening	Baseline	Day of Surgery	Early PostOP	FU d3	FU d14	FU d30	FU every 12w
I/E criteria	✓	-	-	-	-	-	-	-
Demographics, medical history	✓	-	-	-	-	-	-	-
Written informed consent	-	✓	-	-	-	-	-	-
Vital signs (heart frequency, blood pressure, body temperature), weight	-	✓	-	✓	✓	✓	✓	✓
Physical examination	-	✓	-	✓	✓	✓	✓	✓
Neurological examination (NANO scale)	-	✓	-	✓	✓	✓	✓	✓
Orthoptic examination	-	✓	-	-	-	✓	-	-
Seizure status (ILAE)	-	✓	✓	✓	✓	✓	✓	✓
Current medication (including steroids)	-	✓	✓	✓	✓	✓	✓	✓
ASA score	-	✓	-	-	-	-	-	-
KPS	-	✓	-	✓	✓	✓	✓	✓
MMSE	-	✓	-	-	-	✓	✓	✓
Modified Rankin score (mRS)	-	✓	-	✓	✓	✓	✓	✓
Neurocognitive testing (BLTT)	-	✓	-	-	-	-		✓*****
QoL questionnaire (EORTC-QLQ-C30 and BN20)	-	✓	-	-	-	✓	✓	✓ ***
Complete blood count	-	✓	-	✓	✓	-	-	-
Coagulation analysis (including preoperative tests as specified in 2.7)	-	✓	-	✓	-	-	-	-
Serum chemistry	-	✓	-	✓	✓	-	-	-
Pregnancy test **	-	✓	-	-	-	-	-	-
Gadolinium-enhanced MRI	-	✓	-	-	✓	-	-	✓

EEG	-	✓	-	-	-	-	✓	-
Adverse events (CTCAE)	-	-	✓	✓	✓	✓	✓	-
Randomization	-	-	✓	-	-	-	-	-
Surgery-related data (IOM, duration, blood loss, intraoperative seizures etc.)	-	-	✓	-	-	-	-	-
Survival status *	-	-	-	✓	✓	✓	✓	✓
Periprocedural adverse events (PSIs, CSCs)	-	-	-	✓	✓	✓	✓	✓ ****
Length of mechanical ventilation	-	-	-	✓	✓	✓	-	-
Histopathological results	-	-	-	-	-	-	✓	-
Length of hospital stay	-	-	-	-	-	✓	✓	✓
Radiotherapy (day of start, number of days, total Gy)	-	-	-	-	-	✓	✓	✓
Tumor-directed medical therapy (drug, dose, schedule)	-	-	-	-	-	✓	✓	✓
Other tumor-directed treatment (e.g. TTFs)	-	-	-	-	-	✓	✓	✓
Assessment of progression (RANO 2.0 criteria)	-	-	-	-	-	-	-	✓

* until end of the trial, i.e. 3 years after randomization of the last patient or until death

** for women with childbearing potential

*** after day 90 visit (first 12 week follow-up): every 24 weeks

**** only until day 90

***** only at day 90 and 12 months post-op (Visits 8 and 11)